PARP inhibitors have revolutionized care for breast cancer patients with germline BRCA1/2 mutations, improving outcomes for patients with advanced/metastatic and high-risk early-stage disease. Capitalizing on these benefits requires widespread adoption of genetic testing among patients with key disease features instead of limiting to those with a strong family history. Additionally, evidence is evolving to expand the use of PARP inhibitors to tumors with other mutations affecting the DNA damage repair (DDR) pathway, further emphasizing the importance of genetic testing. Tune in for a dynamic multidisciplinary discussion featuring prospectives from experts in breast cancer oncology, surgery, and pathology, as they: review the latest clinical evidence for PARP inhibition among breast cancer patients with germline and somatic DDR mutations explore opportunities for integrating guideline-concordant genetic testing within multidisciplinary clinical workflows discuss real-world cases and strategies for using genetic testing results to guide treatment strategy and individualize care in early-stage and advanced/metastatic breast cancer.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/optimizing-parp-inhibitors-early-stage-metastatic-breast-cancer-patients-dna
- Start Date: 2024-11-13 06:00:00
- End Date: 2024-11-13 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 37375.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 13875.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all